	US 11,752,196 B2
	Treatment of pyroptosis
Rajiv Jalan, London (GB); Ugo Soffientini, London (GB); Nigel Beaton, London (GB); and Gautam Mehta, London (GB)
Filed by Rajiv Jalan, London (GB); Ugo Soffientini, London (GB); Nigel Beaton, London (GB); and Gautam Mehta, London (GB)
Filed on Sep. 21, 2020, as Appl. No. 17/26,534.
Application 17/026,534 is a continuation of application No. PCT/GB2019/050814, filed on Mar. 21, 2019.
Claims priority of application No. 1804514 (GB), filed on Mar. 21, 2018.
Prior Publication US 2021/0069296 A1, Mar. 11, 2021
Int. Cl. A61K 38/17 (2006.01); A61P 1/16 (2006.01); A61K 31/27 (2006.01); A61K 31/277 (2006.01); A61K 38/07 (2006.01); A61K 45/06 (2006.01); G01N 33/68 (2006.01)

CPC A61K 38/1793 (2013.01) [A61K 31/27 (2013.01); A61K 31/277 (2013.01); A61K 38/07 (2013.01); A61K 38/1709 (2013.01); A61K 45/06 (2013.01); A61P 1/16 (2018.01); G01N 33/6893 (2013.01); G01N 2800/085 (2013.01)]

6 Claims

1. A method of treating acute-on-chronic liver failure (ACLF) caused by aberrant pyroptosis in an individual in need thereof, said method comprising a step of administering to said individual an antagonist of GSDMD.